HEPATIC FIBROSIS: MECHANISMS OF DEVELOPMENT AND TREATMENT ISSUES
- Autores: Yakovenko E.P.1, Ivanov A.N.1, Pryanishnikova A.S.1, Yakovenko A.V.1, Agafonova N.A.1, Yakovenko EP1, Yakovenko AV1, Ivanov AN1, Agafonov NA1, AS Pryanishnikova -1
-
Afiliações:
- Edição: Nº 12 (2011)
- Páginas: 16-22
- Seção: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/278937
- ID: 278937
Citar
Texto integral
Resumo
Sobre autores
Emiliya Yakovenko
Aleksandr Ivanov
Antonina Pryanishnikova
Andrey Yakovenko
Natal'ya Agafonova
E Yakovenko
A Yakovenko
A Ivanov
N Agafonov
- AS Pryanishnikova
Bibliografia
- Kuntz E, Kuntz HD. Hepatology, Textbook and Atlas. Verlag: Springer Medizin Verlag Heidelberg 2008.
- Bissel DM, Maher JJ. Hepatic fibrosis and cirrhosis. In: Zakim D, Boyer TD. (eds) Hepatology. A textbook of liver disease. 4th ed. Saunders Science (USA) 2003:395-416.
- Friedman SL. Cellular sources of collagen and regulation of collagen production in liver. Semin Liver Dis 1990;10:20-28.
- Albanis E, Friedman SL. Hepatic fibrosis: pathogenesis and principles of therapy. Clin Liver Dis 2001;5:315-34.
- Henderson NC, Iredale JP. Liver fibrosis: cellular mechanisms of progression and resolution. Clin Sci 2007;112:265-80.
- Okuno M, Moriwaki H, Imai S, et al. Retinoids exacerbate rat liver fibrosis by inducing the activation of latent TGF-beta in liver stellate cells. Hepatology 1997;26:913-16.
- Lee JM, Dedhar S, Kalluri R, et al. The epithelial-mesenchеmal transition: new insights in signaling, development and disease. J Cell Biol 2006;172:973-81.
- Zeisberg M, Yang C, Martino M, et al. Fibroblasts derive from hepatocytes in liver fibrosis via epithelial to mesenchymal transition. J Biol Chem 2007;282:23337-347.
- Correll MD. Liver fibrosis: the hepatocyte revisited. Hepatology 2007;46:1659-60.
- Olaso E, Friedeman SL. Molecular regulation of hepatic fibrogenesis. J Hepatol 1998;29:836-47.
- Ghany MG, Kleiner DE, Alter H, et al. Progression of fibrosis in chronic hepatitis C. Gastroenterology 2003;124:97-104.
- Rojkind M, Dunn MA. Hepatic fibrosis. Gastroenterology 1979;76:849-54.
- Некрасова Т. П. Морфологическое исследование в оценке степени фиброза печени // Гепатологический форум, 2007. № 1. C. 11-13.
- Goodman ZD. Grading and staging systems for inflammation and fibrosis in chronic liver diseases. J Hepatol 2007;47:598-607.
- Poynard T. Hepatitis C and B. Management and treatment. 2nd ed. 2004.
- Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis С. The Obsvirc, Metavir, Clinivir and Dosvirc groups. Lancet 1997;349:825-31.
- Fort J, Pilette C, Veal N, et al. Effects of long-term administration of interferon alpha in two models of liver fibrosis in rats. J Hepatol 1998;29:263-68.
- Lee DY, Liu Y. Molecular structure and stereochemistry of silybin A, silybin B, isosilybin A and isosilybin B, isolated from Silybum marianum (milk thistle). J Nat Prod 2003;66:1171-74.
- Saller R, Meier R, Brignoli R. The use of silymarin in the treatment of liver diseases. Drugs 2001;61:2035-63.
- Вoigk G, Stroedter L, Herbst H, et al. Silymarin retards collagen accumulation in early and advanced biliary fibrosis secondary to complete bile duct obliteration in rats. Hepatology 1997;26:643-48.
- Ferenci P, Scherzer TM, Kerschner H, et al. Silibinin is a potent antiviral agent in patients with chronic hepatitis C not responding to pegylated interferon/ribavirin therapy. Gastroenterology 2008;135:1561-67.
- Rockey DC. Antifibrotic therapy in chronic liver disease. Clin Gastroenterol Hepatol 2005;3:95-107.
- Lieber CS, Leo MA, Cao Q, et all. Silymarin retards the progression of alcohol - induced hepatitis fibrosis in baboons. J Clin. Gastroenterol 2003;37:336-39.
- Ferenci P, Dragosics B, Dittrich H, et al. Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver. J Hepatol 1989;9:105.
- Schuppan D, Strosser W, Burkard G, et al. Verminderung der Fibrosierungsaktivität durch Legalon® bei chronischen Lebererkrankungen. Z Allg Med 1998;74:577-84.